Astorg, Goldman acquire HRA Pharma as Riverside exits
February 22, 2016
Astorg and Goldman Sachs have purchased a controlling interest in HRA Pharma from The Riverside Company. The specialty pharmaceutical company focuses on women’s health and endocrinology. Riverside and HRA’s founders reinvested a small minority stake alongside the two new majority shareholders. Since Riverside first backed the company in 2011, HRA has increased revenue by 95% and grown its international presence to more than 80 countries.